BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN SOUTH KOREA

February 9, 2021

← Back to blog page

Cookies

By continuing to use this website, you agree to our Cookie Policy.